Kathleen A. Kemmer
Oncology | Hematology
7500 Challis Rd
Entrance1, Level 1
Brighton, MI 48116
Entrance1, Level 1
Brighton, MI 48116
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 16, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Journal: Nature communications
Published: March 25, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Journal: Cancer cell
Published: December 07, 2020
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
Journal: NPJ breast cancer
Published: November 23, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 24, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Journal: JAMA oncology
Published: February 14, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 08, 2020
Early Prediction of Breast Cancer Therapy Response using Multiresolution Fractal Analysis of DCE-MRI Parametric Maps.
Journal: Tomography (Ann Arbor, Mich.)
Published: March 12, 2019
Implementing a comprehensive translational oncology platform: from molecular testing to actionability.
Journal: Journal of translational medicine
Published: August 14, 2018
DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy Response.
Journal: Tomography (Ann Arbor, Mich.)
Published: July 11, 2017
Adaptive Randomization of Neratinib in Early Breast Cancer.
Journal: The New England journal of medicine
Published: July 14, 2016
Last Updated: 09/26/2026